Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Menveo: Phase II data

Novartis AG (NVS; SWX:NOVN), Basel, Switzerland
Product: Menveo ( MenACWY-CRM vaccine)
Business: Infectious
Molecular

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE